3 results match your criteria: "Department of Laboratory Genetics University Hospital Kralovske Vinohrady[Affiliation]"

The case of a 39-year-old man with slowly growing mass in the superior part of left parotid region is described. Patient presented neurological symptoms including hypomobility of lower left eyelid and inability of complete closure of left side eyelids resulting in conjunctivitis and hyperlacrimation. Routine physical examination supported by image and laboratory tests was performed.

View Article and Find Full Text PDF

Circulating tumour cells in patients with urothelial tumours: Enrichment and in vitro culture.

Can Urol Assoc J

September 2014

Department of Laboratory Genetics University Hospital Kralovske Vinohrady, Prague, Czech Republic; ; Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland.

Introduction: Results of clinical trials have demonstrated that circulating tumour cells (CTCs) are frequently detected in patients with urothelial tumours. The monitoring of CTCs has the potential to improve therapeutic management at an early stage and also to identify patients with increased risk of tumour progression or recurrence before the onset of clinically detected metastasis. In this study, we report a new effectively simplified methodology for a separation and in vitro culturing of viable CTCs from peripheral blood.

View Article and Find Full Text PDF

In vitro culturing of viable circulating tumor cells of urinary bladder cancer.

Int J Clin Exp Pathol

July 2015

Department of Laboratory Genetics University Hospital Kralovske Vinohrady Srobarova 50, 100 97 Prague, Czech Republic ; Department of Histology and Embryology, Wroclaw Medical University Chalubinskiego 6a, 50-368 Wroclaw, Poland ; Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol 105 00 Prague, Czech Republic.

Objective: Approximately one third of patients diagnosed with muscle-invasive urinary bladder cancer (UBC) have undetected metastases at the time of treatment of the primary tumor. Currently there are no reliable specific serum markers for monitoring and evaluating risk profiles of urothelial cancers. Several studies suggest that detection of circulating tumor cells (CTCs) may correlate with the disease status and prognosis at baseline and early in the treatment of cancers.

View Article and Find Full Text PDF